Jane Street Group LLC increased its position in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 13.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,872 shares of the biopharmaceutical company’s stock after purchasing an additional 1,754 shares during the period. Jane Street Group LLC’s holdings in SAGE Therapeutics were worth $2,450,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. raised its holdings in SAGE Therapeutics by 412.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,565 shares in the last quarter. Fortaleza Asset Management Inc. bought a new stake in SAGE Therapeutics during the fourth quarter worth approximately $167,000. First Mercantile Trust Co. bought a new stake in SAGE Therapeutics during the fourth quarter worth approximately $169,000. Envestnet Asset Management Inc. raised its holdings in SAGE Therapeutics by 70.7% during the third quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 1,204 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new stake in SAGE Therapeutics during the fourth quarter worth approximately $213,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of SAGE Therapeutics stock opened at $166.29 on Thursday. SAGE Therapeutics Inc has a one year low of $59.57 and a one year high of $195.97.
SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.98) by $0.23. During the same quarter last year, the company earned ($1.50) EPS. equities analysts forecast that SAGE Therapeutics Inc will post -8.34 earnings per share for the current year.
In other SAGE Therapeutics news, Director Steven M. Paul sold 58,139 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $172.00, for a total transaction of $9,999,908.00. Following the sale, the director now directly owns 632,712 shares of the company’s stock, valued at approximately $108,826,464. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Stephen Kanes sold 44,000 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the sale, the insider now directly owns 46,348 shares in the company, valued at $8,211,938.64. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.
Several equities research analysts recently commented on the company. BidaskClub raised SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $198.00 price target on shares of SAGE Therapeutics in a report on Friday, December 8th. SunTrust Banks upped their price target on SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Morgan Stanley started coverage on SAGE Therapeutics in a report on Monday, February 26th. They issued an “overweight” rating and a $225.00 price target on the stock. Finally, Royal Bank of Canada dropped their price target on SAGE Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a report on Monday, November 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $183.93.
ILLEGAL ACTIVITY WARNING: “SAGE Therapeutics Inc (SAGE) Position Raised by Jane Street Group LLC” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/22/sage-therapeutics-inc-sage-position-raised-by-jane-street-group-llc.html.
SAGE Therapeutics Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.